Interlukin - 6
IL - 6 and Systemic Effects
IL - 6 Inflammatory Pathways
IL -6 Disease Association: Atherosclerosis/Leukemia/COPD/Arthritis
Agents Targeting IL -6 Pathway
Tocilizumab/Sarilumab Indicated For Rheumatoid Arthritis
Tocilizumab
Tocilizumab in Rheumatoid Arthritis
Current Events
IL - 6 Storm
Tocilizumab may be effective for patients with COVID-19, blood cancer
The immunosuppressant tocilizumab may be an effective treatment for very ill individuals with COVID-19 and hematologic malignancies, according to results of a case study from China published in Blood Advances.
Early research suggests the novel coronavirus triggers an excessive immune response and “a strong cytokine storm” that may include high levels of interleukin-6 and granulocyte-macrophage colony-stimulating factor, according to study background.
Snapshot
Tocilizumab For Interlukin Storm
No comments:
Post a Comment